Oncology/Genetics| Volume 169, ISSUE 5, P1213-1220, May 2021

The utility of high-mobility group A2 overexpression for predicting the prognosis of gastric cancer patients and its contribution to poor prognosis via chemoresistance and the propensity for the occurrence of carcinomatosis peritonei

Published:December 26, 2020DOI:


      The aim of this study was to elucidate the correlation of high-mobility group protein A2 overexpression with gastric cancer prognosis and compare its prognostic power with that of pre-existing markers.


      Malignant tissues from 396 patients with gastric cancer who underwent gastrectomy from 2008 to 2012 were examined. High-mobility group protein A2 expression was assessed by immunohistochemistry and the sensitivity and specificity for predicting disease progression and overall survival of high-mobility group protein A2 and the prognostic biomarkers p53, Ki-67, human epidermal growth factor receptor 2, cyclooxygenase-2, and epidermal growth factor receptor were compared.


      A total of 95 samples (24.1%) showed high-mobility group protein A2 overexpression, which was related to advanced stage, undifferentiated histology, and lymphatic and perineural invasion. Additionally, high-mobility group protein A2 overexpression was an independent prognostic factor in multivariate analysis for disease progression and overall survival. Based on Kaplan-Meier survival analysis disease progression and overall survival, the high-mobility group protein A2-overexpressing patients showed worse survival. The recurrence pattern of peritoneal dissemination was more frequently observed in high-mobility group protein A2-positive group. Moreover, chemoresistance was more frequently observed in the high-mobility group protein A2-positive group. High-mobility group protein A2 exhibited a better ability for predicting disease progression and overall survival than other markers, and the prognostic power was enhanced when high-mobility group protein A2 was used with these markers.


      High-mobility group protein A2 overexpression is associated with chemoresistance and a propensity for carcinomatosis peritonei after surgery in patients with gastric cancer. The power to predict the prognosis of patients with gastric cancer can be enhanced with the use of preexisting biomarkers and high-mobility group protein A2.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jung K.W.
        • Won Y.J.
        • Kong H.J.
        • Oh C.M.
        • Lee D.H.
        • Lee J.S.
        Prediction of cancer incidence and mortality in Korea, 2014.
        Cancer Res Treat. 2014; 46: 124-130
        • Jung K.W.
        • Won Y.J.
        • Kong H.J.
        • Oh C.M.
        • Lee D.H.
        • Lee J.S.
        Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011.
        Cancer Res Treat. 2014; 46: 109-123
        • Fidler I.J.
        Critical determinants of metastasis.
        Semin Cancer Biol. 2002; 12: 89-96
        • Steeg P.S.
        Tumor metastasis: mechanistic insights and clinical challenges.
        Nat Med. 2006; 12: 895-904
        • Yasui W.
        • Oue N.
        • Aung P.P.
        • Matsumura S.
        • Shutoh M.
        • Nakayama H.
        Molecular-pathological prognostic factors of gastric cancer: a review.
        Gastric Cancer. 2005; 8: 86-94
        • Steinestel K.
        • Eder S.
        • Schrader A.J.
        • Steinestel J.
        Clinical significance of epithelial-mesenchymal transition.
        Clin Transl Med. 2014; 3: 17
        • Chiurillo M.A.
        Role of the Wnt/beta-catenin pathway in gastric cancer: An in-depth literature review.
        World J Exp Med. 2015; 5: 84-102
        • Wu C.
        • Zhuang Y.
        • Jiang S.
        • et al.
        Interaction between Wnt/beta-catenin pathway and microRNAs regulates epithelial-mesenchymal transition in gastric cancer (review).
        Int J Oncol. 2016; 48: 2236-2246
        • Dong J.
        • Wang R.
        • Ren G.
        • et al.
        HMGA2-FOXL2 axis regulates metastases and epithelial-to-mesenchymal transition of chemoresistant gastric cancer.
        Clin Cancer Res. 2017; 23: 3461-3473
        • Li W.
        • Wang Z.
        • Zha L.
        • Kong D.
        • Liao G.
        • Li H.
        HMGA2 regulates epithelial-mesenchymal transition and the acquisition of tumor stem cell properties through TWIST1 in gastric cancer.
        Oncol Rep. 2017; 37: 185-192
        • Wang H.
        • Jiang Z.
        • Chen H.
        • Wu X.
        • Xiang J.
        • Peng J.
        MicroRNA-495 inhibits gastric cancer cell migration and invasion possibly via targeting high mobility group at-hook 2 (HMGA2).
        Med Sci Monit. 2017; 23: 640-648
        • Li W.
        • Li J.
        • Mu H.
        • Guo M.
        • Deng H.
        MiR-503 suppresses cell proliferation and invasion of gastric cancer by targeting HMGA2 and inactivating WNT signaling pathway.
        Cancer Cell Int. 2019; 19: 164
        • Reeves R.
        • Nissen M.S.
        The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure.
        J Biol Chem. 1990; 265: 8573-8582
        • Rogalla P.
        • Drechsler K.
        • Frey G.
        • et al.
        HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors.
        Am J Pathol. 1996; 149: 775-779
        • Sgarra R.
        • Rustighi A.
        • Tessari M.A.
        • et al.
        Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer.
        FEBS Lett. 2004; 574: 1-8
        • Motoyama K.
        • Inoue H.
        • Nakamura Y.
        • Uetake H.
        • Sugihara K.
        • Mori M.
        Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family.
        Clin Cancer Res. 2008; 14: 2334-2340
        • Kong D.
        • Su G.
        • Zha L.
        • et al.
        Coexpression of HMGA2 and Oct4 predicts an unfavorable prognosis in human gastric cancer.
        Med Oncol. 2014; 31: 130
        • Jun K.H.
        • Jung J.H.
        • Choi H.J.
        • Shin E.Y.
        • Chin H.M.
        HMGA1/HMGA2 protein expression and prognostic implications in gastric cancer.
        Int J Surg. 2015; 24: 39-44
        • Lee J.
        • Ha S.
        • Jung C.K.
        • Lee H.H.
        High-mobility-group A2 overexpression provokes a poor prognosis of gastric cancer through the epithelial-mesenchymal transition.
        Int J Oncol. 2015; 46: 2431-2438
        • Chung H.W.
        • Lim J.B.
        High-mobility group box-1 contributes tumor angiogenesis under interleukin-8 mediation during gastric cancer progression.
        Cancer Sci. 2017; 108: 1594-1601
        • Chung H.W.
        • Jang S.
        • Kim H.
        • Lim J.B.
        Combined targeting of high-mobility group box-1 and interleukin-8 to control micrometastasis potential in gastric cancer.
        Int J Cancer. 2015; 137: 1598-1609
        • Bang Y.J.
        • Van Cutsem E.
        • Feyereislova A.
        • et al.
        Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
        Lancet. 2010; 376: 687-697
        • Kunz P.L.
        • Mojtahed A.
        • Fisher G.A.
        • et al.
        HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.
        Appl Immunohistochem Mol Morphol. 2012; 20: 13-24
        • Joo Y.E.
        • Chung I.J.
        • Park Y.K.
        • et al.
        Expression of cyclooxygenase-2, p53 and Ki-67 in gastric cancer.
        J Korean Med Sci. 2006; 21: 871-876
        • Zhen Y.
        • Guanghui L.
        • Xiefu Z.
        Knockdown of EGFR inhibits growth and invasion of gastric cancer cells.
        Cancer Gene Ther. 2014; 21: 491-497
        • Ando K.
        • Oki E.
        • Saeki H.
        • et al.
        Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancer.
        Cancer Med. 2015; 4: 75-83
        • Badary D.M.
        • Abdel-Wanis M.E.
        • Hafez M.Z.
        • Aboulhagag N.A.
        Immunohistochemical analysis of PTEN, HER2/neu, and ki67 expression in patients with gastric cancer and their association with survival.
        Pathophysiology. 2017; 24: 99-106
        • Hofmann M.
        • Stoss O.
        • Shi D.
        • et al.
        Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
        Histopathology. 2008; 52: 797-805
        • Zhu J.
        • Wang H.
        • Xu S.
        • Hao Y.
        Clinicopathological and prognostic significance of HMGA2 overexpression in gastric cancer: a meta-analysis.
        Oncotarget. 2017; 8: 100478-100489
        • Nie D.
        • Zhang L.
        • Guo Q.
        • Mao X.
        High mobility group protein A2 overexpression indicates poor prognosis for cancer patients: a meta-analysis.
        Oncotarget. 2018; 9: 1237-1247
        • Boku N.
        HER2-positive gastric cancer.
        Gastric Cancer. 2014; 17: 1-12
        • Abrahao-Machado L.F.
        • Scapulatempo-Neto C.
        HER2 testing in gastric cancer: An update.
        World J Gastroenterol. 2016; 22: 4619-4625
        • Yoo H.J.
        • Kim T.J.
        • Kim D.J.
        • Kim W.
        Role of COX2 as a biomarker for estimating survival of patients with clinical stage I gastric cancer.
        Anticancer Res. 2020; 40: 341-347
        • Hosmer D.
        • Lemeshow S.
        Applied Logistic Regression.
        2nd ed. John Wiley and Sons, New York2000
        • Kim M.R.
        • Choi H.K.
        • Cho K.B.
        • Kim H.S.
        • Kang K.W.
        Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells.
        Cancer Sci. 2009; 100: 1834-1841
        • Wang Z.
        • Li Y.
        • Kong D.
        • Banerjee S.
        • et al.
        Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.
        Cancer Res. 2009; 69: 2400-2407
        • Shang Y.
        • Cai X.
        • Fan D.
        Roles of epithelial-mesenchymal transition in cancer drug resistance.
        Curr Cancer Drug Targets. 2013; 13: 915-929
        • Sun J.
        • Sun B.
        • Zhu D.
        • et al.
        HMGA2 regulates CD44 expression to promote gastric cancer cell motility and sphere formation.
        Am J Cancer Res. 2017; 7: 260-274
        • Kanda M.
        • Kodera Y.
        Molecular mechanisms of peritoneal dissemination in gastric cancer.
        World J Gastroenterol. 2016; 22: 6829-6840
        • Yonemura Y.
        • Endou Y.
        • Fujita H.
        • et al.
        Role of MMP-7 in the formation of peritoneal dissemination in gastric cancer.
        Gastric Cancer. 2000; 3: 63-70
        • Zeng W.
        • Zhu J.
        • Shan L.
        • et al.
        The clinicopathological significance of CDH1 in gastric cancer: a meta-analysis and systematic review.
        Drug Des Devel Ther. 2015; 9: 2149-2157
        • Hu Y.
        • Qi C.
        • Liu X.
        • et al.
        Malignant ascites-derived exosomes promote peritoneal tumor cell dissemination and reveal a distinct miRNA signature in advanced gastric cancer.
        Cancer Lett. 2019; 457: 142-150